We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CANC hit a 52-week high after surging more than 3% on Aug. 19.
Moderna's melanoma trial success boosted sentiment across oncology stocks.
CANC's positive weighted alpha of 66.73 signals potential for further gains.
Tema Oncology ETF (CANC - Free Report) is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and has surged 72.8% from its 52-week low price of $26.24 per share.
Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed.
CANC in Focus
The Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. The CANC ETF consists of 58 total holdings, with the top 10 constituting 40.20% of the fund's assets. The leading holdings include Revolution Medicines Inc (6.02%), Eli Lilly & Co (5.01%), and Cogent Biosciences Inc (4.99%). The product charges 75 bps in annual fees.
Why the Move?
Merck and Moderna recently announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its endpoints for recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected Stage IIB-IV melanoma. Moderna stock surged 177% on Aug. 19, 2026 while Merck shares gained 12.6% on the day. The news acted as a cornerstone for the whole cancer investing space, boosting the pure-play fund.
More Gains Ahead?
The ETF gained over 3% on Aug. 19, 2026. CANC might continue its strong performance in the near term, with a positive weighted alpha of 66.73 (per Barchart.com), which hints at a rally.
View the Zacks #1 Rank List
Image: Bigstock
Biotech ETF (CANC) Hits New 52-Week High
Key Takeaways
Tema Oncology ETF (CANC - Free Report) is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and has surged 72.8% from its 52-week low price of $26.24 per share.
Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed.
CANC in Focus
The Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. The CANC ETF consists of 58 total holdings, with the top 10 constituting 40.20% of the fund's assets. The leading holdings include Revolution Medicines Inc (6.02%), Eli Lilly & Co (5.01%), and Cogent Biosciences Inc (4.99%). The product charges 75 bps in annual fees.
Why the Move?
Merck and Moderna recently announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its endpoints for recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected Stage IIB-IV melanoma. Moderna stock surged 177% on Aug. 19, 2026 while Merck shares gained 12.6% on the day. The news acted as a cornerstone for the whole cancer investing space, boosting the pure-play fund.
More Gains Ahead?
The ETF gained over 3% on Aug. 19, 2026. CANC might continue its strong performance in the near term, with a positive weighted alpha of 66.73 (per Barchart.com), which hints at a rally.